Everest Medicines reports slight rise in issued shares

Everest Medicines Limited reported a slight increase in its total number of issued shares for the month ended October 31, 2025, reaching 353,548,381. This represents an increase of 13,000 shares from the previous month's total of 353,535,381. The company's authorized/registered share capital remained constant at 500,000,000 ordinary shares with a par value of $0.0001, totaling $50,000.

The increase in issued shares was primarily driven by the exercise of share options. During October 2025, 13,000 new shares were issued pursuant to the Pre-IPO Employee Share Option Plan and Post-IPO share option scheme, raising HK$254,092. As of October 31, 2025, 173,573 shares remain available for issue under the Pre-IPO employee share option plan, and 21,841,838 shares under the Post-IPO share option scheme.

Additionally, the company granted 1,311,374 shares under the Post-IPO share option scheme and 234,800 restricted stock units under the Pre-IPO employee share option plan during the month. Also, 79,438 restricted stock units and 100,000 awards vested, while 132,172 share options, 33,302 restricted stock units, and 47,771 awards were cancelled.